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bstract
ackground  and  purpose:  World Health Organization estimated that there were 600,000 new cases of head and neck cancers and 300,000 deaths
ach year worldwide. Scientific modalities to predict the treatment outcomes are not available yet. We conducted this study to (1) compare CT
erfusion parameters before and after chemoradiation among patients with head and neck squamous cell carcinoma and (2) to evaluate the prognostic
alue of each perfusion parameter in predicting the response to chemoradiation.
aterials  and  methods:  We conducted a prospective study among all patients with head and neck squamous cell carcinoma registered for
hemoradiotherapy (CRT) at Regional Cancer Research Center, Shimla, Himachal Pradesh, India during the period June 2012 through June 2013.
Tp data were acquired on a 64-slice CT scanner (Light speed VCT Xte; GE Healthcare) with 14 cm z-axis coverage using Volume Helical Shuttle
VHS) feature at baseline, on completion of 40 Gy and 66 Gy of chemoradiation. We dichotomised the treatment outcome as complete response and
on-response (partial responders/stable disease/progressive disease) using RECIST 1.1 criteria. We compared all perfusion parameters at baseline,
0 Gy and 66 Gy of CRT between responders and non-responders. We dichotomised the perfusion parameters as high (>median value) and low
≤median value) to analyze association between perfusion parameters and treatment outcome. We calculated the sensitivity, specificity, predictive
alues, and likelihood ratios for each dichotomized perfusion parameter using Wilson Score method.
esults:  We followed 24 patients (23 of them men) from start of the treatment till completion of it. All had Stage III or Stage IV of the disease.
lood flow (BF) and blood volume (BV) decreased and Mean Transit Time (MTT) increased significantly (p  < 0.05) at 66 Gy among responders
o CRT as compared to non-responders. Patients with high BF (>106 ml/100 g/min) at baseline were five times more likely (p  = 0.004) to respond
o treatment as compared to those with low BF. BF was found to be 83.3% predictive of complete response. Other perfusion parameters were not
eywords: CT perfusion; Perfusion parameters; Chemoradiation; Head and neck squamous cell carcinoma; RECIST 1.1
Abbreviations: BF, blood flow; BV, blood volume; CECT, contrast enhanced computed tomography; CR, complete responder; CRT, chemotherapy and radiation
herapy; CTP, perfusion computed tomography; CT, computed tomography; HNSCC, head and neck squamous cell carcinoma; MVD, microvascular density; PD,
rogressive disease; PR, partial responder; PS, permeability surface area product; RECIST, response evaluation criteria in solid tumors; ROI, region of interest; SCC,
quamous cell carcinoma; SCCA, squamous cell carcinoma of aerodigestive tract.
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ignificantly predictive of outcome (p  > 0.05) Combination of high BF (>106 ml/100 g/min) and low (≤47 ml/100 g/min) permeability surface (PS)
as 100% predictive of response to CRT irrespective of the stage of tumor.
onclusions:  High BF at baseline is the single best predictor of response to chemoradiaton. A combination of high BF and low PS was found to
e 100% predictive of complete response irrespective of the stage of the tumor.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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.  Introduction
CTp (computed tomography perfusion) has emerged as a
on-invasive functional imaging tool providing quantitative
arameters regarding angiogenesis and tumor perfusion which
an predict the response, monitor the effects and assess long term
reatment outcome in HNSCC (head and neck squamous cell car-
inoma) [1–3]. CTp can explore the molecular nature of tumor
erfusion in addition to information about size and enhancement
f tumor as done with conventional CT (computed tomography)
4–7].
MVD (microvascular density) which is pathological marker
f angiogenesis is considered as predictor of response in
NSCC. MVD requires endoscopic biopsy and is an invasive
rocedure accompanied by its own risks. CTp is a non-invasive
easurement of intra tumoral MVD which has a prognostic
alue [7,8].
Studying dynamics of perfusion parameters of tumor help
n understanding the therapy induced functional changes in
umor tissue and help in distinguishing responders from non-
esponders [9].
CTp studies revealed that HNSCC have increased BF, BV,
S and reduced MTT as compared to normal tissue and benign
esions [10,11]. In different studies conducted, during the course
f chemo-radiation, responders showed a significant reduction
n BF and BV whereas non-responders showed a non-significant
levation of BF and BV [9,12,13].
The purpose of our study was to evaluate the role of CTp
n histologically proven HNSCC in predicting the treatment
esponse before the commencement of therapy, determine the
hanges in perfusion parameters during the course of treatment
nd after completion of chemoradiation. Four perfusion param-
ters namely BF, BV, PS and MTT were assessed quantitatively
nd analyzed to determine which one of these perfusion param-
ters co-related well with treatment outcome as per RECIST 1.1
riteria.
.  Methods
.1.  Patient  selection
We conducted this prospective study among patients who met
he following criteria:
. Histopathologic or cytologic evidence of squamous cell car-
cinoma of head and neck staged according to 2002 American
Joint Committee on Cancer Classification.
. Registered for CRT (chemoradiotherapy) at Regional Cancer
Research Center of our hospital.
s
e
t. No prior history of chemotherapy/radiotherapy/CRT for any
condition.
. No contra-indication to iodinated contrast medium adminis-
tration.
Patients with terminal illness, inability to communicate, or
nwilling to participate in the study were excluded.
A written informed consent was obtained from all participants
nd the proposal was approved by institutional ethics committee.
We performed non-enhanced computed tomography
NECT), CTp and contrast enhanced computed tomography
CECT) of the neck before the commencement of treatment,
fter 40 Gy of platinum based chemoradiotherapy and again at
he end (66 Gy) of treatment.
.2.  Technique
Patients were trained for quite breathing and not to swallow
uring the procedure. NECT of neck was acquired to localize
he tumor with following parameters – 100 kV, 50–220 mA with
utomated tube current modulation, 0.8 s rotation time, 5 mm
hickness and total exposure time of 5 s. The scan position was
djusted to cover the entire volume.
CTp of neck was performed on a 64-slice CT scanner (Light
peed VCT Xte; GE Healthcare) with Z-axis coverage of 14 cm.
ifty ml of iodinated non-ionic contrast with iodine concen-
ration of 370 mg/ml was injected at a rate of 5 ml/s followed
y saline flush of 30 ml with an automated pressure injector
Stellant, MEDRAD) through the antecubital vein on the side
pposite to the tumor to reduce streak artifacts from large veins.
canning was initiated 5 s after the start of injection and images
ere acquired for duration of 35.86 s. The parameters used were
 100 kV, 50–220 mA with automated tube current modulation,
.4 s rotation time, 5 mm thickness and noise index of 15 and
he processing of perfusion was done on 5/5 mm slice. Immedi-
tely after CTp, CECT of the neck was performed from thoracic
nlet to the level of skull vault with the same parameters as
hat for NECT. Acquisition was done 40 s after the injection of
.25 ml/kg of iodinated contrast administration.
.3.  Image  processing
Images and data obtained were transferred to an image
rocessing workstation – Advantage windows 4.2, GE Health-
are. Perfusion maps were generated by deconvolution
echnique using vendor’s Perfusion CT 4 (GE) software. No
eparate motion correction program was available. The program
stimates tissue perfusion as the maximum slope of the tumor
ime-density curve divided by the peak arterial enhancement.
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Attenuation thresholds were fixed to exclude bones. Arterial
nput was obtained drawing ROI 4–6 pixel size placed over ICA
xcept in two patients in which ROI was put in ipsilateral IJV
s software did not analyze parameters when ROI was placed
n ICA. Last pre-enhancement and post enhancement images
ere chosen to generate the functional color maps. Unprocessed
ource images in the phase demonstrating maximal enhancement
nd base images were used to draw a freehand ROI at the mar-
in of the tumor. Necrotic areas, vessels and calcifications were
xcluded. Values of BV, BF, and MTT & PS were measured in all
ections depicting the tumor and the mean value was calculated.
.4.  Statistical  analysis
We dichotomised the treatment outcome as complete
esponse and non-response (partial responders/stable dis-
ase/progressive disease) using RECIST 1.1 criteria. For all
easurements taken at different points in time, we tested for nor-
ality of distribution by Shapiro Wilk test and for inequality of
ariances by Bartlett’s test. A p-value of 0.05 or above was taken
s indicative of normality of data distribution and homogeneity
f variances respectively. The normally distributed indepen-
ent sets of data with homogenous variances were compared by
-test or one way ANOVA and data with non-normal distribution
ere compared by non-parametric tests (Kruskal Wallis test or
riedman test). We compared means of each perfusion param-
ter at baseline for RECIST outcome category. The changes in
erfusion parameters overtime were compared by paired t-test
r Kruskal Wallis test for each category of RECIST response.
e dichotomotized the perfusion parameter values by taking
edian as the cut off – high (>median value) and low (≤median
alue). We conducted a bivariate analysis with dichotomized per-
usion parameter values as exposure variable and dichotomized
esponse as outcome variable. We compared the response rates
RR) in each exposure group and constructed 95% confidence
ntervals around the point estimates. We calculated point esti-
ates and 95% confidence intervals for sensitivity, specificity,
redictive positive values, negative predictive values, likelihood
atios positive and likelihood ratios negative by Wilson Score
ethod. Except for statistical tests for normality of data and
r
d
d
6
able 1
aseline characteristics of the lesion type, size, and perfusion parameters (all values 
easurement Type of squamous cell carcinoma
Well differentiated (n = 10) Moderately differentiated (n = 
arget lesion size (cm.) 4.1 ± 1.1 4.0 ± 1.3 
ymph node size (cm.) 1.6 ± 1.1 1.4 ± 0.5 
erfusion parameters
Fb (ml/100 g/min) 124.5 ± 33.5 103.7 ± 34.7 
Vc (ml/100 g) 12.3 ± 4.5 11.3 ± 3.1 
TTd (s) 6.9 ± 0.9 7.8 ± 1.9 
Se (ml/100 g/min) 45.7 ± 14.3 57.4 ± 17.9 
a Standard deviation.
b Blood flow.
c Blood volume.
d Mean transit time
e Permeability surface.adiology Open 2 (2015) 46–54
omogeneity of variances, p-values ≤  0.05 were treated as sta-
istically significant. We analyzed data using EpiInfo version
.1.4 for windows (http://wwwn.cdc.gov/epiinfo/7/).
.  Results
.1.  Characteristics  of  the  study  participants
Twenty four patients (23 of them men) with HNSSC and
 mean age of 57.9 ±  4.5 years were included in our study.
ineteen (79.1%) patients were in stage III of the disease and
emaining in stage IV disease according to 2002 American
oint Committee on Cancer Classification. Majority (10; 41.7%)
atients had well differentiated SCC, followed by seven (29.1%)
ith moderately differentiated carcinoma histo-pathologically
Table 1). Measurements of target lesions, lymph node size and
ll perfusion parameters did not differ statistically by the type
f squamous cell carcinoma (p  > 0.05).
At the end of chemoradiation, complete remission was
chieved by 12 (50%), partial response by nine patients and three
atients had static disease. None of the patients had progressive
isease (Table 2).
.2.  Perfusion  parameters
At baseline BF was the only perfusion parameters that was
ignificantly higher (p  = 0.006) among responders as compared
o non-responders (Table 3).
During the course of chemoradiation, BF and BV both
educed significantly at 66 Gy in complete responders (p  < 0.05)
s compared to partial responders or patients with static dis-
ase. MTT in complete responders showed a slight temporary
eduction at 40 Gy, which was followed by a rebound as mea-
ured at 66 Gy (p  = 0.024) but changes in partial-responders and
on-responders were not significant. PS values in the complete
esponders were almost stable after 40 Gy and insignificantly
ecreased at 66 Gy (p  = 0.233) whereas in partial respon-
ers PS showed reduction at 40 Gy, which continued after
6 Gy (p  = 0.032). In non-responders there was statistically
expressed in mean ± sd).a
7) Poorly differentiated (n = 2) Un-classified (n = 5) All lesions (n = 24)
3.9 ± 0.9 5.7 ± 2.8 4.4 ± 1.7
1.3 ± 0.6 1.8 ± 0.6 1.5 ± 0.8
102.7 ± 9.4 81.8 ± 17.8 107.7 ± 33.0
8.3 ± 7.0 8.5 ± 2.2 10.9 ± 4.0
5.0 ± 4.2 7.8 ± 1.5 7.2 ± 1.8
62.5 ± 24.8 49.9 ± 12.7 51.4 ± 15.9
L.
 Rana
 et
 al.
 /
 European
 Jo
u
rn
al
 of
 Radiology
 O
pen
 2
 (2015)
 46–54
 
49
Table 2
Comparison of perfusion parameters at baseline, 40 GYa CRTb and 66 Gy CRT stratified by response to CRT (n = 24).
Perfusion parameter Responders (n = 12) Partial responders (n = 9) Static disease (n = 3)
Baseline 40 Gy CRT 66 Gy CRT p-Value Baseline 40 Gy CRT 66 Gy CRT p-Value Baseline 40 Gy CRT 66 Gy CRT p-Value
BFc (ml/100 g/min) 125.3 ± 25.7 122.7 ± 32.4 82.5 ± 36.3 0.002 86.7 ± 20.8 118.9 ± 39.1 85.4 ± 21.0 0.050 100.3 ± 56.5 92.1 ± 9.3 72.0 ± 28.5 0.264
BVd (ml/100 g) 12.2 ± 3.5 13.8 ± 6.6 10.1 ± 5.9 0.005 8.4 ± 2.6 12.5 ± 7.0 7.5 ± 2.7 0.147 13.4 ± 6.7 7.7 ± 0.7 7.3 ± 3.1 0.097
MTTe (seconds) 7.0 ± 1.2 7.1 ± 2.4 8.4 ± 2.2 0.024 7.1 ± 2.4 7.3 ± 2.2 6.2 ± 1.6 0.124 8.4 ± 1.5 5.7 ± 1.6 7.7 ± 0.9 0.178
PSf (ml/100 g/min) 48.7 ± 10.6 48.7 ± 14.9 41.2 ± 23.6 0.233 58.4 ± 16.3 38.3 ± 20.2 36.7 ± 13.4 0.032 41.0 ± 28.6 54.7 ± 38.1 18.5 ± 8.3 0.097
a Gray unit.
b Chemo-radiotherapy.
c Blood flow.
d Blood volume.
e Mean transit time.
f Permeability Surface.
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nsignificant elevation of PS at 40 Gy and reduction at 66 Gy
p = 0.097; Table 2).
Prognostically, patients with high BF were five times more
ikely to respond to chemoradiation as compared to patients with
ow BF (Table 4) and the difference was statistically significant
p = 0.004). High BF in our study was found to have 83.3% pro-
nostic accuracy, sensitivity, specificity and positive predictive
alue each (Table 5).
On graphical analysis (Fig. 1) BF of ≥85 ml/100 g/min was
redictor of complete response to treatment in 11 (73.3%) out
f 15 patients. Out of 12 completer responders, 11 (92.0%) had
F above 85 ml/100 g/min.
Positive predictive value (PPV) of high BV was next to high
F, followed by low MTT and low PS (Table 5).
After stratifying the patients in four different patterns of com-
ination of perfusion parameters [15] i.e. High BF with high
S, High BF with low PS, low BF with high PS and low BF
ith low PS, there was 100% response to treatment in the per-
usion parameter combination of high BF and low PS while
6.6% complete responders were seen with high BF and high
S combination irrespective of the stage of HNSCC (Table 6).
.3.  Bivariate  analysis
On bivariate analysis, patients with high blood flow were
ound to be five times more likely to respond as compared to
he patients with low BF at baseline. Other perfusion parameters
ere not significantly associated with the response probably due
o low power of the study (Table 4).
.  Discussion
Angiogenesis is an important aspect of tumorigenesis. Pri-
ary stimulus for new vessel formation is presumed to be
ypoxia induced by expansion of growing cellular tumor mass.
ypoxia induces the expression of HIF-1, VEGF, PDGF and
arbonic anhydrase IX [14]. Goh at el [15] have reported that
umor vessels are different and show arteriovenous shunting,
ntermittent or reverse flow. In the center of the tumor there
s decline of vascular density with higher number of elongated
ompressed vessels having high intervessel and interbranch dis-
ances. There is acute vascular collapse due to raised interstitial
ressure. The endothelial lining of tumor vessel wall has loose
ndothelial connections, bigger openings and lack in smooth
uscle and pericyte covering. Defective endothelium causes
ascular hyperpermeability which results in raised intratumoral
nterstitial pressure.
The changes happening at vascular level cannot be assessed
y RECIST 1.1 which is still considered as gold standard for
ssessing the tumor response to chemo-radiotherapy [16,17].
Tp assesses not only the tumor morphology but is a func-
ional imaging biomarker reflecting angiogenesis and can predict
umor response to treatment and vascular changes after treatment
ven before there is reduction in the tumor size [12].
The Z-axis coverage in CT perfusion of head and neck varied
rom 1 cm to 2.5 cm in different studies [8,18]. Limited coverage
esulted in centering of the perfusion study at the level of the
L. Rana et al. / European Journal of Radiology Open 2 (2015) 46–54 51
Table 4
Association between perfusion parameter value at baseline and response to chemo radiation (n = 24).
Perfusion parameter Complete response Risk Ratio 95% CIa p-Value
High value (>median) Low value (≤median)
No. Total % No. Total %
Blood Flow (median = 106 ml/100 g/min) 10 12 83.3 2 12 16.7 5.00 1.38–18.2 0.004
Blood volume (median = 10.1 ml/100 g) 7 11 63.6 5 13 38.5 1.65 0.73–3.76 0.413
Mean transit time (median = 6.9 s) 4 11 36.4 8 13 61.5 0.59 0.24–1.44 0.413
Permeability surface (median = 47.0 ml/100 g/min) 5 12 41.7 7 12 58.3 0.71 0.31–1.62 0.683
a Confidence interval.
Fig. 1. Post contrast CT (a), source image (b), BF (c), BV (d) MTT (e) and PS (f) maps.
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argest tumor diameter only. However due to heterogeneity of
he tumor and its perfusion parameters whole tumor volume
hould be encompassed in the perfusion protocols.
Dynamic CT perfusion can be performed using cine mode,
 combination of cine and axial modes or a toggling table tech-
ique [19]. Axial CT perfusion allows discontinuous scanning
nd the area of coverage is 4 cm only as there is no table
oggling motion. Though cine CT perfusion allows axial con-
inuous scanning but area of coverage of 4 cm only. In the
resent study, CTp was done with Z-axis coverage of 14 cm
sing the Volume Helical Shuttle [VHS] that enabled visu-
lization of entire tumuor. With wider z-axis coverage tumor
eterogeneity is better assessed because whole tumor perfusion
arameters can be quantified at all levels and necrotic areas can
e excluded while calculating the perfusion parameters. Accord-
ng to ACR–ASNR–SPR practice guideline for the performance
f computed tomography (CT) perfusion in neuroradiologic
maging [20], “in toggling table technique, the temporal resolu-
ion at each location should be no less than 1 image per second.”
n the VHS with use of Dynamic Pitch Cone Beam Reconstruc-
ion (DPCB), VT patient table and advanced real-time control,
xtended z-coverage and Tuned Auto mA the resulting image at
he central location of scan is scanned or has an average temporal
ampling of 1.5 s.
Our results show that responders had significant higher base-
ine BF values than the non-responders. Similar results have
een found not only in HNSCC but also in rectal and lung
alignancies. Tumors adapt to hypoxia by promoting more neo-
ngiogenesis leading to higher BF and PS. Low tumor perfusion
ndicates less blood flow to the tumor which in turn impairs the
elivery of the chemotherapeutic agents, hypoxia also decreases
adiosensitivity [21]. Another study [22] concluded that pre-
reatment tumor BF was significantly higher in responders. Our
ndings were in partial agreement with another study [23] which
howed the long-term predictive value of baseline BF and PS
easurements from CTp imaging for local control in 84 patients
ndergoing chemoradiation.
Perfusion parameters were compared according to the vol-
me of the tumor. Patients having higher BF at baseline showed
ignificant reduction in volume while patient having low BF
ere non-responder for volume reduction [p  = 0.003]. There was
o statistically significant correlation in BV, MTT and PS values
mong responders and non-responders. Similar methodology
as been done by Zima et al. [9] but they employed invasive
ndoscopic procedure for this calculation.
Goh et al. [15] divided perfusion parameters of a tumor into
our different patterns of vascularization – high BF and high PS
s matched vascularization, high BF and low PS as high intersti-
ial pressure, low BF and high PS as mismatched vascularization
nd low BF and low PS as necrosis. In our study we combined
F and PS in these four categories and to predict the response
o treatment. After stratifying the patients in four different pat-
erns of combination of perfusion parameters i.e. high BF with
igh PS, high BF with low PS, low BF with high PS and low
F with low PS, there was 100% response to treatment in the
erfusion parameter combination of high BF and low PS while
6.6% complete responders were seen with high BF and high PS
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Table 6
Predictive value of different combination of baseline blood flow (BF) and permeability surface (PS).
Blood flow and permeability Participants (n = 24) Stage of the tumor (n = 24) Complete response
No. % Stage III Stage IV No. %
No. % No. %
Higha BF and Lowb PS 6 25.0 4 66.7 2 33.3 6 100.0
High BF and High PS 6 25.0 6 100.0 0 0.0 4 66.7
Low BF and High PS 6 25.0 4 66.7 2 33.3 1 16.7
Low BF and Low PS 6 25.0 4 66.7 2 33.3 1 16.7
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ombination irrespective of the stage of HNSCC. We observed
hat relying only on morphological criteria for staging may be
nadequate and perfusion status of tumor plays more important
ole in determining the response of the tumor to the treatment.
s this doctrine has already been included in the PERCIST crite-
ia for solid tumor evaluation, we propose that CTP parameters
hould also be incorporated along with RECIST criteria or alone
or tumor evaluation. Due to wide availability of MDCT as com-
ared to PET-CT, CTp appears to be good alternative to PET-CT
specially in the developing countries.
We attempted to classify HNSCC into histopathological types
nd TNM staging and evaluate their perfusion parameters to
ompare them with RECIST 1.1 criteria. However, changes in
hem were not statistically significant. CTp values, therefore, are
ot dependent on the histopathological subtypes.
In responders, BF showed decreasing trend at 40 Gy and
6 Gy of treatment and this change was statistically significant
p = 0.002). BV increased at 40 Gy but decreased at 66 Gy of
RT which was statistically significant (p  = 0.005). MTT also
howed statistically significant (p  = 0.024) increase at 40 Gy
nd 66 Gy. This is attributed to cytotoxic effect of radiotherapy
o the vascular endothelial cells. The fluctuation of perfusion
arameters during the course of therapy is due to hypoxia and
ntratumoral inflammation as hypoxia may lead to decrease
n perfusion and inflammation further lead to increase in BF
nd PS. Changes in PS values were not statistically significant
p = 0.233).
In partial responders, BF increased at 40 Gy and thereafter
ecreased significantly (p  = 0.050) at 66 Gy. The changes in
alues of BV, MTT and PS were statistically insignificant.
In patients with stable disease (non-responders) changes in
ll the perfusion parameters at baseline, 40 Gy and 66 Gy were
tatistically insignificant.
The serial study done at baseline, 40 Gy and 66 Gy revealed
hat the change in perfusion parameters at 40 Gy is not reliable
o predict response as compared to changes at completion of
herapy. Therefore CTp done at 40 Gy appears to be clinically
nsignificant and can be done away with.
.  ConclusionsHigh BF at baseline is the single best predictor of response
o chemoradiaton. A combination of high BF and low PS was
ound to be 100% predictive of complete response irrespective
[f the stage of the tumor. CTp parameter measurements at 40 GY
f chemoradation are not indicative for response to treatment.
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